Thrombocytopenia Purpura
Anti-idiotypic antibodies to antiplatelet antibodies are common in idiopathic TP
Published in Blood Weekly, November 27th, 2003
According to a study from India, "The severity and clinical course of idiopathic thrombocytopenic purpura (ITP) varies from patient to patient. The factors responsible for this variation are not well understood. In this study we attempted to evaluate the role of anti-idiotypic antibodies in the immunoregulation of the disease.
"We investigated 114 cases of chronic ITP in adults. We determined anti-idiotypic antibodies against antiplatelet antibodies using idiotype-binding ELISA, paratope-blocking ELISA,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2003-11-27)
More Articles from Blood Weekly
- Multiple Myeloma
Recombinant erythropoietin enables stem cell autografting without RBC transfusions - Stem-Cell Transplantation
Granulocyte transfusions can prevent post-SCT infections - Hematology
Superparamagnetic labeling enables stromal cell tracking - Multiple Myeloma
Ho-166-DOTMP with stem-cell autografting shows promise against MM in early studies - Multiple Sclerosis
Immunosuppression therapy with stem-cell transplant ineffective in severe progressive MS - Stem-Cell Transplantation
Infliximab shows promise for treatment of gastrointestinal GVHD - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
